NextCure to Present at H.C. Wainwright Neuro Perspectives Conference

NextCure, Inc., a clinical-stage biopharmaceutical company listed on Nasdaq under the symbol NXTC, has announced its participation in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference. The event is set to take place on Thursday, June 27, 2024. NextCure will present and conduct meetings with institutional investors during the conference. A webcast recording of the presentation will be accessible on the conference day starting at 7 AM ET through the Investors section on the company's website. This webcast will remain available for 30 days.

NextCure specializes in the discovery and development of innovative therapies for cancer and other diseases. Among its prominent projects are NC410, a LAIR-2 fusion protein, and LNCB74, a novel antibody-drug conjugate (ADC) that targets B7-H4. Additionally, the company is working on a non-oncology preclinical asset, NC181. This humanized antibody is designed to target ApoE4 for treating Alzheimer's disease.

NextCure focuses on pioneering first-in-class and best-in-class treatments, leveraging unique therapeutic mechanisms to address unmet medical needs. The company’s research and development efforts are dedicated to creating breakthrough therapies that can significantly improve patient outcomes.

The upcoming participation in the Neuro Perspectives Virtual Conference underscores NextCure’s commitment to engaging with the investment community and sharing valuable updates on its progress. The company aims to attract attention to its cutting-edge pipeline and ongoing clinical developments.